After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The company said the safety profile remained consistent with earlier studies and was considered manageable
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
